Editas med stock.

Shares of Editas Medicine (EDIT 2.28%) were soaring 11.2% higher as of 10:41 a.m. ET on Friday after vaulting as much as 24% earlier in the day. The big gain …Stock Price Forecast. According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an increase of 31.81%. The lowest target is $7.00 and the highest is $36. On average, analysts rate EDIT stock stock as a buy.Finance. Industry. MarketPrecise correction of the CD40LG gene in T cells and hematopoietic stem/progenitor cells (HSPC) holds promise for treating X-linked hyper-IgM Syndrome (HIGM1), but its actual therapeutic potential remains elusive. Here, we developed a one-size-fits-all editing strategy for effective T-cell correctio …

Although this will not come as news to anyone who’s been on any one of the most common psychiatric medicatio Although this will not come as news to anyone who’s been on any one of the most common psychiatric medications prescribed — such as...Nov 21, 2023 · The Editas Medicine stock prediction results are shown below and presented as a graph, table and text information. Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53. Today 200 Day Moving Average is the resistance level ...

Aug 23, 2023 · That's why companies such as Editas Medicine ( EDIT 0.86%) and Intellia Therapeutics ( NTLA 2.54%) are down massively over the trailing 12-month period. However, Wall Street expects both to bounce ...

See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.As of March 31, 2023, Editas Medicine had $401.8 million in cash, cash equivalents, and marketable securities, which is expected to fund their operating expenses and capital expenditures until 2025.Jan 26, 2021 · Editas Medicine ( EDIT 0.86%) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Over the past year, it has more than doubled investors' money. Meanwhile, the ... CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Editas Medicine (NASDAQ: EDIT) has extended post-market gains to rise ~9% in early trading on Tuesday after the company announced a favorable decision issued by U.S. patent officials backing the ...

Founded. 2013. ISIN. US28106W1036. Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic …

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update.

As of June 1, 2023, Editas Medicine Inc’s stock price is $9.55, which is up 4.03% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics ...Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Apr 3, 2023 · Editas Medicine (EDIT 0.86%) sits at the bleeding edge of biotech's hottest field, gene editing to treat inherited diseases. The company has shifted its focus to a product it is testing for severe ... In brief, Editas Medicine's lack of commercialized products, early-stage pipeline, pipeline setback, and termination of a strategic alliance with AbbVie have all hurt the stock's performance.The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $3.19 above the current market price. The public float for EDIT is 81.05M and currently, short sellers hold a 19.58% of that float. On November 29, 2023, EDIT’s average trading volume was 1.64M shares.

Legal Name Editas Medicine, Inc. Stock Symbol NASDAQ:EDIT. Company Type For Profit. Contact Email [email protected]. Phone Number (617) 401-9000. Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to …Stock Price Forecast. According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an increase of 31.81%. The lowest target is $7.00 and the highest is $36. On average, analysts rate EDIT stock stock as a buy.Why Editas Medicine Stock Is Soaring Today. By Keith Speights – Sep 29, 2023 at 11:21AM Key Points. Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17.Editas Medicine (EDIT) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.Discover historical prices for EDIT stock on Yahoo Finance. View daily, weekly or monthly format back to when Editas Medicine, Inc. stock was issued.

Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Shares of Editas Medicine ( EDIT 3.66%) were jumping 7% as of 11:53 a.m. EDT on Monday after rising as much as 20.2% earlier in the day. The gain came after another CRISPR-focused biotech ...Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …Jan 13, 2022 · Shares of Editas Medicine ( EDIT -2.58%) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. The company presented at the ... 1.76%. $20.2M. Plandai Biotechnology Inc. -20.00%. $1.94M. CRSP | Complete CRISPR Therapeutics AG stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Full details of the Editas Medicine presentations can be accessed in the Posters & Presentations section on the Company’s website.. About EDIT-103 EDIT-103 is a CRISPR/Cas9-based experimental ...Dec 10, 2020 · This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...

Editas Medicine, Inc. 2020 Q2 - Results - Earnings Call Presentation. SA Transcripts Thu, Aug. 06, 2020. 1 2. All earnings call transcripts on Editas Medicine, Inc. (EDIT) stock. Read or listen to ...

This week was a significant bounce back after Editas' shares stumbled following an announcement by the company on Jan. 9 that it was suspending some of its programs and cutting about 20% of its ...

Oct 7, 2023 · Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ... Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of ...Jun 20, 2023 · On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ... EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Nov 20, 2022 · Editas Medicine ended the third quarter with $478.5 million in cash and equivalents, compared to $657 million as of Q3 2021. It reported a net loss of $55.7 million during the period, worse than ... Aquí nos gustaría mostrarte una descripción, pero el sitio web que estás mirando no lo permite.Editas (EDIT) delivered earnings and revenue surprises of 14.06% and 5.50%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?November 28, 2022 — 01:08 pm EST. Shares of Editas Medicine, Inc. EDIT have plunged 32.6% in the past three months against the industry ’s increase of 6.9%. The company is developing its lead ...Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on or about January 25, 2021, subject to customary closing conditions.CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update.

In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.In brief, Editas Medicine's lack of commercialized products, early-stage pipeline, pipeline setback, and termination of a strategic alliance with AbbVie have all hurt the stock's performance.This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...Instagram:https://instagram. largest lab grown diamondbest day trader brokeragebest platform for currency tradingquarter bicentennial Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). banks that give same day debit cardscrowdsourced real estate platforms Editas Medicine (NASDAQ: EDIT), a genome-editing company, has seen a significant 20% surge in its stock, marking its largest increase over two years.This comes despite a 4.9% dip year-to-date and ...Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. bj wholesale stock The high in the last 52 weeks of Editas Medicine stock was 11.93. According to the current price, Editas Medicine is 89.88% away from the 52-week high. What are …Investment Thesis. Earlier this year, I wrote an article highlighting Editas Medicine's ( NASDAQ: EDIT) sluggish pace in which it is advancing its drug development programs. Since then, the ...